Skip to main content
Clinical Trials/NCT05957653
NCT05957653
Not yet recruiting
Phase 4

Lidocaine Combined With Sufentanil for Preventing Catheter-related Bladder Discomfort After Robot-assisted Radical Prostatectomy: a Randomized, Double-blind, Controlled Trial

RenJi Hospital0 sites140 target enrollmentOctober 7, 2023

Overview

Phase
Phase 4
Intervention
lidocaine and sufentanil
Conditions
Prostate Cancer
Sponsor
RenJi Hospital
Enrollment
140
Primary Endpoint
incidence of CRBD
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

The goal of this clinical trial is to evaluate the incidence and severity of postoperative catheter-related bladder discomfort after robot-assisted radical prostatectomy.

The main question it aims to answer is to evaluate incidence of CRBD immediately after extubation in resuscitation.

A total of 20ml of 2% lidocaine and 1μg/ml sufentanil or 20ml normal saline was injected into the bladder of the participants through the catheter. After drug injection, the catheter was clamped for 20 minutes, and then 100ml normal saline was injected into the bladder through the catheter to flush out.

Then, the incidence of CRBD was compared between the two groups.

Registry
clinicaltrials.gov
Start Date
October 7, 2023
End Date
October 30, 2025
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Male

Investigators

Responsible Party
Principal Investigator
Principal Investigator

zhuhao

attending physician

RenJi Hospital

Eligibility Criteria

Inclusion Criteria

  • aged 18-79 years, ASA class I-II
  • participants undergoing robot-assisted radical prostatectomy under general anesthesia
  • signed informed consent and volunteered to participate in the experiment

Exclusion Criteria

  • urethral stricture, difficulty in inserting catheter or urethral bleeding during catheterization
  • a preexisting bladder disease such as an overactive bladder, bladder outflow obstruction, and neurogenic bladder
  • cognitive impairment or communication disorders
  • severe heart, lung, liver, kidney and immune system diseases
  • confirmed or suspected allergy to this trial drug

Arms & Interventions

Lidocaine + sufentanil intervention group

Intervention: lidocaine and sufentanil

Saline control group

Intervention: Saline

Outcomes

Primary Outcomes

incidence of CRBD

Time Frame: immediately after extubation in resuscitation

incidence of CRBD

Similar Trials